Ani Pharmaceuticals (ANIP) Share-based Compensation (2010 - 2026)

Ani Pharmaceuticals has disclosed Share-based Compensation across 17 years of filings, most recently posting $11.4 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 18.79% year-over-year to $11.4 million; the TTM figure through Jun 2026 stood at $41.1 million (up 24.35% YoY), while the FY2025 annual figure was $37.9 million, up 29.26% from the prior year.
• Share-based Compensation came in at $11.4 million for Q2 2026 at Ani Pharmaceuticals, up from $10.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $11.4 million in Q2 2026 to a low of $1.1 million in Q2 2022.
• Average Share-based Compensation over 5 years is $6.6 million, with a median of $7.0 million recorded in 2024.
• Year-over-year, Share-based Compensation plunged 58.63% in 2022 and soared 373.39% in 2023.
• Over 5 years, Share-based Compensation stood at $3.7 million in 2022, then jumped by 50.41% to $5.6 million in 2023, then climbed by 25.62% to $7.1 million in 2024, then soared by 38.34% to $9.8 million in 2025, then gained by 16.77% to $11.4 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $11.4 million in Q2 2026, $10.2 million in Q1 2026, and $9.8 million in Q4 2025.